Enlivex LTD. (ENLV) — SEC Filings

Overview

Enlivex LTD. (ENLV) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Apr 21, 2026: Enlivex Ltd. filed a Form 6-K on April 21, 2026, reporting information as a foreign issuer. The filing includes a press release (EX-99.1) and other documents related to the company's operations. The company is based in Tel Aviv, Israel.

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 9 bullish, 1 bearish, 39 neutral, 1 mixed. The dominant filing sentiment for Enlivex LTD. is neutral.

Filing Type Overview

Enlivex LTD. (ENLV) has filed 47 6-K, 2 20-F, 1 SC 13G with the SEC between May 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• Enlivex Ltd. Files Form 6-K with SEC — 6-K · Apr 21, 2026 Risk: low
  Enlivex Ltd. filed a Form 6-K on April 21, 2026, reporting information as a foreign issuer. The filing includes a press release (EX-99.1) and other documents re
• Enlivex Files Routine 6-K, Includes Press Release — 6-K · Mar 26, 2026
  Enlivex Ltd. filed a 6-K report on March 26, 2026, indicating a routine foreign issuer report. This filing includes a current report and a press release, sugges
• Enlivex Pivots to Crypto Treasury, Reports Non-Cash Gain Amidst Clinical Losses — 20-F · Mar 25, 2026 Risk: high
  Enlivex Ltd. (ENLV) reported a dual strategy for the fiscal year ended December 31, 2025, combining clinical development of Allocetra™ for inflammatory conditio
• Enlivex Secures Financing via Convertible Note with Lind G — 6-K · Mar 24, 2026
  Enlivex Ltd. filed a 6-K on March 24, 2026, detailing a Securities Purchase Agreement dated March 23, 2026, with Lind G, which includes a Senior Secured Convert
• 6-K Filing — 6-K · Dec 18, 2025
• 6-K Filing — 6-K · Dec 4, 2025
• Enlivex Therapeutics Closes Private Placement — 6-K · Nov 26, 2025 Risk: medium
  Enlivex Therapeutics Ltd. announced the closing of its previously reported private placement on November 24, 2025. The company, organized under the laws of Isra
• 6-K Filing — 6-K · Nov 24, 2025
• 6-K Filing — 6-K · Nov 18, 2025
• Enlivex Therapeutics Files 6-K with Financials — 6-K · Nov 14, 2025 Risk: low
  Enlivex Therapeutics Ltd. filed a Form 6-K on November 14, 2025, reporting its unaudited condensed consolidated financial statements as of and for the period en
• 6-K Filing — 6-K · Nov 10, 2025
• Enlivex Therapeutics Ltd. Files 6-K Report — 6-K · Sep 25, 2025 Risk: low
  Enlivex Therapeutics Ltd. filed a Form 6-K on September 25, 2025, reporting on its activities as a foreign private issuer. The filing indicates the company's pr
• Enlivex Therapeutics Ltd. CEO Letter to Shareholders — 6-K · Sep 11, 2025 Risk: low
  On September 11, 2025, Enlivex Therapeutics Ltd. issued a letter from its CEO to shareholders. The letter provided an update on the company's progress and strat
• Enlivex Therapeutics Secures Israeli Patent for Cancer Drug — 6-K · Sep 9, 2025 Risk: medium
  Enlivex Therapeutics Ltd. announced on September 9, 2025, the issuance of an Israeli patent for its drug candidate, Allocetra. This patent covers the use of All
• Enlivex Therapeutics Files 6-K Update — 6-K · Aug 29, 2025 Risk: medium
  Enlivex Therapeutics Ltd. filed a Form 6-K on August 29, 2025, reporting its financial statements for the period ending June 30, 2025. The company, formerly kno
• Enlivex Therapeutics Reports Positive Phase 2b Data — 6-K · Aug 18, 2025 Risk: medium
  On August 18, 2025, Enlivex Therapeutics Ltd. announced three-month topline data from its Phase 2b clinical trial for Allocetra. The data showed a statistically
• Enlivex Therapeutics to Host Webinar on August 18 — 6-K · Aug 14, 2025 Risk: low
  Enlivex Therapeutics Ltd. announced on August 14, 2025, that it will host a webinar on August 18, 2025, at 8:00 AM Eastern Time. The webinar will provide an upd
• Enlivex Therapeutics Completes Phase II COVID-19 Trial Enrollment — 6-K · Jul 28, 2025 Risk: medium
  On July 28, 2025, Enlivex Therapeutics Ltd. announced that all 134 patients in the Phase II stage of its randomized, controlled trial for its drug Allocetra hav
• Enlivex Therapeutics Files 6-K with Financials — 6-K · May 30, 2025 Risk: low
  Enlivex Therapeutics Ltd. filed a Form 6-K on May 30, 2025, reporting its unaudited condensed consolidated financial statements for the three-month periods ende
• Enlivex Therapeutics Files 2024 Annual Report — 20-F · Apr 30, 2025 Risk: medium
  Enlivex Therapeutics Ltd. filed its annual report on Form 20-F for the fiscal year ended December 31, 2024. The company, formerly known as Bioblast Pharma Ltd.,
• Enlivex Therapeutics to Present at OARSI 2025 World Congress — 6-K · Apr 23, 2025 Risk: low
  On April 23, 2025, Enlivex Therapeutics Ltd. announced it will present two poster abstracts at the Osteoarthritis Research Society International (OARSI) 2025 Wo
• Enlivex Completes Patient Enrollment for Phase II COVID-19 Trial — 6-K · Apr 21, 2025 Risk: medium
  On April 21, 2025, Enlivex Therapeutics Ltd. announced the completion of patient enrollment for the Phase II stage of its randomized, controlled, blinded Phase
• Enlivex Doses First Patient in Phase I Trial — 6-K · Apr 3, 2025 Risk: medium
  On April 3, 2025, Enlivex Therapeutics Ltd. announced that the first patient has been dosed in an investigator-initiated Phase I trial. This trial will evaluate
• Enlivex Therapeutics Files 2024/2023 Financial Statements — 6-K · Mar 31, 2025 Risk: low
  Enlivex Therapeutics Ltd. filed a Form 6-K on March 31, 2025, reporting its audited consolidated financial statements for the years ended December 31, 2024, and
• Enlivex Therapeutics Secures China Patent Allowance for Sepsis Treatment — 6-K · Mar 17, 2025 Risk: medium
  On March 17, 2025, Enlivex Therapeutics Ltd. announced that the China National Intellectual Property Administration issued a notice of allowance for a patent re
• Enlivex Therapeutics to Discuss Phase I Trial Data — 6-K · Mar 4, 2025 Risk: medium
  On March 4, 2025, Enlivex Therapeutics Ltd. announced a webinar for investors scheduled for March 5, 2025, at 11:00 a.m. ET. The webinar will discuss positive i
• Enlivex Therapeutics Reports Positive Phase II Trial Data — 6-K · Mar 3, 2025 Risk: medium
  On March 3, 2025, Enlivex Therapeutics Ltd. announced positive interim six-month efficacy data from the first stage of its Phase II Allocetra™ trial. The trial
• Enlivex Therapeutics Addresses Fraudulent News — 6-K · Feb 18, 2025 Risk: medium
  On February 18, 2025, Enlivex Therapeutics Ltd. issued an urgent statement addressing fraudulent news circulating about the company. The company, formerly known
• Enlivex Therapeutics gets Israeli MoH approval for Phase I sepsis trial — 6-K · Dec 11, 2024 Risk: medium
  On December 11, 2024, Enlivex Therapeutics Ltd. announced that the Israeli Ministry of Health has authorized the initiation of a Phase I investigator-initiated
• Enlivex Therapeutics Reports Positive Phase I Data for Allocetra™ — 6-K · Dec 3, 2024 Risk: medium
  On December 3, 2024, Enlivex Therapeutics Ltd. announced positive interim efficacy data from the Phase I stage of its randomized, multi-country Phase I/II trial
• Enlivex Therapeutics Files 6-K with Q3 Financials — 6-K · Nov 29, 2024 Risk: low
  Enlivex Therapeutics Ltd. filed a Form 6-K on November 29, 2024, reporting its unaudited condensed consolidated financial statements for the three and nine mont
• Enlivex Therapeutics to Buy Up to $1M in Bitcoin — 6-K · Nov 20, 2024 Risk: medium
  On November 20, 2024, Enlivex Therapeutics Ltd. announced that its board of directors approved the purchase of up to $1 million in Bitcoin. This strategic move
• Enlivex Doses First Patient in Phase I Solid Tumor Trial — 6-K · Nov 14, 2024 Risk: medium
  Enlivex Therapeutics Ltd. announced on November 14, 2024, the completion of dosing and initial follow-up for the first patient in its Phase I clinical trial. Th
• SC 13G Filing — SC 13G · Nov 14, 2024
• Enlivex Therapeutics Enrolls First 10 Patients in Phase II Trial — 6-K · Nov 12, 2024 Risk: medium
  Enlivex Therapeutics Ltd. announced on November 12, 2024, the enrollment and dosing of the first 10 patients in the Phase II stage of its clinical trial for its
• Enlivex Therapeutics Holds 2024 Annual Shareholder Meeting — 6-K · Nov 8, 2024 Risk: low
  Enlivex Therapeutics Ltd. held its 2024 Annual General Meeting of Shareholders on November 7, 2024. The company, organized under the laws of Israel, is headquar
• Enlivex Therapeutics 2024 Shareholder Meeting Fails Due to Lack of Quorum — 6-K · Oct 31, 2024 Risk: medium
  Enlivex Therapeutics Ltd. held its 2024 Annual General Meeting of Shareholders on October 31, 2024. The meeting was convened but was not able to proceed due to
• Enlivex Therapeutics Secures Japanese Patent Allowance — 6-K · Oct 30, 2024 Risk: low
  On October 30, 2024, Enlivex Therapeutics Ltd. announced that the Japanese Patent Office issued a notice of allowance for patent application number 2022-512861.
• Enlivex Therapeutics Gets Green Light for Phase II COVID-19 Trial — 6-K · Sep 26, 2024 Risk: medium
  On September 26, 2024, Enlivex Therapeutics Ltd. announced that the Danish Medicines Agency has authorized the initiation of the Phase II stage of its clinical
• Enlivex Therapeutics Trial Continues After Positive DSMB Review — 6-K · Sep 24, 2024 Risk: medium
  On September 24, 2024, Enlivex Therapeutics Ltd. announced that the independent Data and Safety Monitoring Board (DSMB) completed an interim data review for its
• Enlivex Therapeutics Files September 2024 6-K Report — 6-K · Sep 11, 2024 Risk: low
  Enlivex Therapeutics Ltd. filed a Form 6-K on September 11, 2024, reporting on its activities for the month of September 2024. The filing is a report of a forei
• Enlivex Therapeutics Files 6-K with Financials — 6-K · Aug 30, 2024 Risk: medium
  Enlivex Therapeutics Ltd. filed a Form 6-K on August 30, 2024, reporting its unaudited condensed consolidated financial statements for the period ending June 30
• Enlivex Therapeutics Gets Green Light for Phase I Trial — 6-K · Jul 23, 2024 Risk: medium
  On July 23, 2024, Enlivex Therapeutics Ltd. announced that the Israeli Ministry of Health has authorized the initiation of a Phase I clinical trial for their dr
• Enlivex Doses First Patient in COVID-19 Trial — 6-K · Jun 24, 2024 Risk: medium
  On June 24, 2024, Enlivex Therapeutics Ltd. announced that the first patient has been dosed in an investigator-initiated, randomized, placebo-controlled Phase I
• Enlivex Therapeutics to Host Investor Webinar — 6-K · Jun 20, 2024 Risk: low
  Enlivex Therapeutics Ltd. announced on June 20, 2024, that it will host an investor webinar on June 25, 2024, at 4:15 p.m. ET. The webinar will provide an updat
• Enlivex Therapeutics Reports Positive Phase I/II Trial Data — 6-K · Jun 17, 2024 Risk: medium
  On June 17, 2024, Enlivex Therapeutics Ltd. announced positive interim data from a Phase I/II investigator-initiated clinical trial for its drug candidate, Allo
• Enlivex Therapeutics Files 6-K with Financial Updates — 6-K · Jun 14, 2024 Risk: low
  Enlivex Therapeutics Ltd. filed a Form 6-K on June 14, 2024, reporting its unaudited condensed consolidated financial statements for the three-month periods end
• Enlivex Therapeutics Gets Green Light for COVID-19 Trial — 6-K · Jun 3, 2024 Risk: medium
  On June 3, 2024, Enlivex Therapeutics Ltd. announced it received regulatory authorization to begin an investigator-initiated, randomized clinical trial for its
• Enlivex Therapeutics Enters Securities Purchase Agreement — 6-K · May 29, 2024 Risk: medium
  On May 27, 2024, Enlivex Therapeutics Ltd. entered into a securities purchase agreement with a single investor. The company, incorporated in Israel, is a pharma
• Enlivex Therapeutics Secures $5M Private Placement — 6-K · May 28, 2024 Risk: medium
  On May 28, 2024, Enlivex Therapeutics Ltd. announced a definitive agreement with a single healthcare-focused institutional investor for a private placement. The

Related Companies

ENLX · ENRX

Frequently Asked Questions